MedNexus
2019年 · 第47卷第07期
MedNexus
- 全部
- 总编随笔
- 专题笔谈
- 指南与共识
- 结构性心脏病
- 临床研究
- 基础研究
- 病例报告
- 综述
- 继续教育园地
In 2019, a piece of drug information widely spread on WeChat, "Aspirin has stepped down from the altar", caused great confusion among the public. First of all, this message does not clearly distinguish between the different status of aspirin in primary prevention and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), citing the newly published important clinical trial results of three negative results of aspirin in primary prevention, completely denying the role of aspirin in preventing (including secondary prevention) ASCVD; On the other hand, different interpretations and positions have emerged in academic circles regarding the latest clinical evidence and foreign guideline recommendations of aspirin in the primary prevention of ASCVD.
本期目次

